Using disease models to accelerate Huntington’s disease research

""

Currently, no effective cure or treatment for Huntington’s disease exists. To accelerate Huntington’s disease research and drug discovery, researchers need access to physiologically relevant human disease models that recapitulate patient phenotypes, in combination with more advanced methods to understand the underlying mechanisms of the disease.

Download this new App Note from bit.bio to learn:

  • How Charles River Laboratories characterised the phenotype of a human iPSC-derived Huntington’s disease model from bit.bio over 38 days in vitro with high-density microelectrode arrays from MaxWell Biosystems.
  • How the disease model demonstrates physiologically relevant phenotypes, including delayed neuronal network formation, decreased axonal branching and decreased spontaneous activity compared to the isogenic control.
  • How the Huntington’s disease model from bit.bio can be used with a genetically matched control, forming an isogenic system that allows scientists to attribute experimental outcomes directly to the disease-causing mutation.

Download the App Note now.

 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free